A larger number of tumours with no VHL alteration would be needed to validate further our hypotheses through prospective clinical trials, and non-VHL molecular pathways that are involved in CCRCC should be better characterised. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.